恩度联合化疗治疗晚期非小细胞肺癌的临床观察.pdfVIP

中国实用医药20 14年7月第9卷第 19期　China Prac Med, Jul 20 14, Vol. 9, No. 19 ·39· 恩度联合化疗治疗晚期非小细胞肺癌的 临床观察 汤虹　王莉莉　牛海红　张哲　王启鸣　罗素霞 【摘要 】　 目的　评价重组人血管 内皮抑制度 ( 恩度 ) 联合化疗治疗晚期非小细胞肺癌的疗效和不 良 反应 。方法　 12 1 例晚期非小细胞肺癌患者 , 按随机数字表法分成两组 , 其 中 58 例恩度联合化疗治疗 ( 试 验组 ) ；63 例仅接受化疗 ( 对照组 ) 。观察两组 的近期总有效率 、临床获益率和疾病进展时间。结果　 试验组总有效率 37.93%(22/58), 对照组为 19.05%(12/63), 两组 比较差异有统计学意义 (P0.05) ；试验组 临床获益率为 81.03%(47/58), 对照组为 63.49%(40/63), 两组 比较差异有统计学意义 (P0.05) ；试验组 的 中位疾病进展时间为 7.9 个月 , 对照组为 6.3 个月 (P0.05) 。试验组每个周期 的药物不 良反应发生率与 对照组发生率 的比较差异无统计学意义 (P0.05) 。结论　恩度联合化疗治疗晚期非小细胞肺癌临床疗效 显著 , 可延长疾病进展时间 , 耐受性好 , 值得临床推广应用 。 【关键词 】　恩度 ; 非小细胞肺癌 ; 疾病进展时间 Clinical observation on recombinant human endostain combined with chemotherapy in advanced non-small cell lung cancer TANG Hong, WANG Li-li, NIU Hai-hong, et al. Tumor Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, China 【Abstract 】　 Obj ective　To investigate effect and safety of recombinant human endostain(rh- endostatin) combined with chemotherapy in advanced non-small cell lung cancer. Methods Divided 12 1 patients with histologically diagnosed advanced non-small cell lung cancer into two groups. The study group(receiving rh-endostatin combined with chemotherapy) had 58 patients and control group (receiving chemotherapy only) had 63 patients. The short-term response rate(RR) , clinical benefit rate(CBR) and time to progression(TTP) were evaluated. Results The short-term response rate(RR) in study group was 37.93%(22/58), while in the control group was 19.05%( 12/63)(P0.05). The clinical benefit rate (CBR) in study group was 8 1.03%(47/58), while in the control group was 63.49%(40/63)(P0.05). The TTP was 7.9 months in study group, while which was 6.3 months in the control group, there was a significant difference between the t